MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer

BACKGROUND: Primary systemic treatment for ovarian cancer is surgery, followed by platinum based chemotherapy. Platinum resistant cancers progress/recur in approximately 25% of cases within six months. We aimed to identify clinically useful biomarkers of platinum resistance. METHODS: A database of o...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMC Cancer
Päätekijät: Pénzváltó, Zsófia, Lánczky, András, Lénárt, Julianna, Meggyesházi, Nóra, Krenács, Tibor, Szoboszlai, Norbert, Denkert, Carsten, Pete, Imre, Győrffy, Balázs
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2014
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4247127/
https://ncbi.nlm.nih.gov/pubmed/25408231
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-837
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia